|
Market Closed -
Nasdaq
16:00:00 2026-08-26 EDT
|
5-day change | 1st Jan Change | ||
| 22.02 USD | +0.18% |
|
+1.29% | -17.77% |
| 08-18 | Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating | MT |
| 08-07 | Amphastar Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
Company Valuation: Amphastar Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,114 | 1,354 | 2,963 | 1,785 | 1,231 | 936.7 | - | - |
| Change | - | 21.52% | 118.8% | -39.75% | -31.07% | -23.88% | - | - |
| Enterprise Value (EV) 1 | 1,114 | 1,354 | 2,963 | 2,235 | 1,231 | 1,240 | 1,121 | 994.3 |
| Change | - | 21.52% | 118.8% | -24.56% | -44.95% | 0.77% | -9.62% | -11.29% |
| P/E | 18.6x | 16.1x | 23.8x | 12.1x | 13.2x | 10.1x | 8.34x | 8.88x |
| PBR | - | - | - | 2.41x | 1.55x | 1.06x | - | - |
| PEG | - | 0.4x | 0.5x | 0.7x | -0.4x | 1.46x | 0.4x | -1.47x |
| Capitalization / Revenue | 2.55x | 2.71x | 4.6x | 2.44x | 1.71x | 1.25x | 1.19x | 1.16x |
| EV / Revenue | 2.55x | 2.71x | 4.6x | 3.05x | 1.71x | 1.66x | 1.43x | 1.23x |
| EV / EBITDA | 11.2x | 9.21x | 10.4x | 7.18x | 4.97x | 5.8x | 5.26x | 4.74x |
| EV / EBIT | 14.5x | 11.1x | 12.1x | 8.66x | 5.7x | 6.85x | 6.08x | 5.11x |
| EV / FCF | - | 20.8x | - | 13x | 10.2x | 9.12x | 9.34x | 7.83x |
| FCF Yield | - | 4.81% | - | 7.71% | 9.85% | 11% | 10.7% | 12.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.25 | 1.74 | 2.6 | 3.06 | 2.03 | 2.17 | 2.64 | 2.48 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 437.8 | 499 | 644.4 | 732 | 719.9 | 747.7 | 784.4 | 808.2 |
| EBITDA 1 | 99.1 | 147.1 | 283.9 | 311.1 | 247.5 | 213.9 | 213.1 | 209.7 |
| EBIT 1 | 76.9 | 121.8 | 245.8 | 258.2 | 215.9 | 180.9 | 184.4 | 194.4 |
| Net income 1 | 62.12 | 91.39 | 137.5 | 159.5 | 98.09 | 99.32 | 115.4 | 111.1 |
| Net Debt 1 | - | - | - | 450 | - | 303.4 | 184.1 | 57.6 |
| Reference price 2 | 23.29 | 28.02 | 61.85 | 37.13 | 26.78 | 22.02 | 22.02 | 22.02 |
| Nbr of stocks (in thousands) | 47,849 | 48,331 | 47,907 | 48,081 | 45,952 | 42,538 | - | - |
| Announcement Date | 3/10/22 | 2/28/23 | 2/28/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 10.15x | 1.66x | 5.8x | -.--% | 937M | |
| 33.86x | 12.29x | 24.9x | 0.58% | 1,060B | |
| 30.03x | - | - | 1.99% | 651B | |
| 33.56x | 7.77x | 16.15x | 2.61% | 465B | |
| 20.52x | 4.87x | 12.06x | 2.71% | 365B | |
| 22.43x | 5.77x | 14.31x | 2.77% | 300B | |
| 21.39x | 4.38x | 12.52x | 2.01% | 258B | |
| 27.85x | 7.18x | 12.75x | 2.29% | 238B | |
| 13.86x | 4.91x | 10.27x | 3.71% | 210B | |
| -45.25x | 6.53x | 25.49x | 2.23% | 184B | |
| Average | 16.84x | 6.15x | 14.92x | 2.09% | 373.13B | |
| Weighted average by Cap. | 24.66x | 8.19x | 18.08x | 1.93% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMPH Stock
- Valuation Amphastar Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
